Palisade Bio, Inc. announced the promotion of Robert McRae to Chief Operating Officer. Additionally, the Company has announced the appointment of J.D. Finley, interim Chief Executive Officer of Palisade Bio, to its Board of Directors. Mr. McRae joined Palisade Bio as Senior Vice President, Operations and Strategic Development in December 2021.

In his new role as Chief Operating Officer, Mr. McRae will be responsible for the oversight of the overall corporate operations as well as executing the strategic R&D and business development related initiatives for the advancement of Palisade. Mr. McRae's experience includes roles in clinical operations and management of global clinical trials in indications across all phases of development. Prior to joining Palisade Bio, Mr. McRae held several positions at Viracta Therapeutics including VP, Operations & Strategic Alliances.

During his tenure Viracta, he was instrumental in developing strategic academic and pharmaceutical partnerships as well as guiding R&D operations including clinical, regulatory and translational activities to effectively execute global trials. Mr. McRae also supported Viracta's transition from private to public. Prior to joining Viracta, Mr. McRae held positions in both business development and study management for a global clinical research organization.

Mr. McRae conducted molecular biology and microbiology research at Wright State University and the United States Air Force Research Laboratory.